 |
 |

Stereotactic Pallidotomy in the Treatment of Parkinson Disease
An Expert Opinion
Jeff M. Bronstein, MD, PhD;
Antonio DeSalles, MD, PhD;
Mahlon R. DeLong, MD;
for the Workshop Participants
Arch Neurol. 1999;56:1064-1069.
The objective of this workshop was to provide recommendations on several issues involving pallidotomy for patients with medically intractable Parkinson disease to physicians, patients, and other health care providers. An international consortium of experts in neurology, neurosurgery, and neurophysiology who had extensive experience with pallidotomy were invited to the workshop. Participants were sent background materials from the scientific literature for review-based participant recommendations. A proposed agenda was circulated to all participants before the workshop, and the final agenda was based on their recommendations. Topics were introduced at the workshop by members of the organizing committee, followed by extensive group discussion. A draft of a consensus statement, based on the previous day's discussion, was circulated and further modifications were made. The final statement was agreed on by all members.The conclusions of the participants were: (1) Pallidotomy should be performed only at centers that have a team of physicians with substantial expertise and experience in the field. (2) Patients with disabling idiopathic Parkinson disease, without dementia, and who have exhausted medical therapy should be considered for pallidotomy. (3) All patients should be examined by means of standardized rating scales both preoperatively and postoperatively to ensure quality of care at each center. (4) Symptoms that respond best to pallidotomy include medication-induced dyskinesias, rigidity, and tremor, while balance, gait disorders, and hypophonia are generally less responsive to surgery. Benefits of pallidotomy appear to be long lasting. (5) Each institution's complication rate should be discussed before surgery.
From the Departments of Neurology (Dr Bronstein) and Neurosurgery (Dr DeSalles) and the Brain Research Institute (Drs Bronstein and DeSalles), University of California, Los Angeles, School of Medicine; and Department of Neurology, Emory School of Medicine, Atlanta, Ga (Dr DeLong).
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(9):1169-1171.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Bilateral subthalamotomy in Parkinson's disease: initial and long-term response
Alvarez et al.
Brain 2005;128:570-583.
ABSTRACT
| FULL TEXT
Bilateral pallidotomy for treatment of Parkinson's disease induced corticobulbar syndrome and psychic akinesia avoidable by globus pallidus lesion combined with contralateral stimulation
Merello et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:611-614.
ABSTRACT
| FULL TEXT
Pathophysiology of bradykinesia in Parkinson's disease
Berardelli et al.
Brain 2001;124:2131-2146.
ABSTRACT
| FULL TEXT
Outcome of unilateral pallidotomy in advanced Parkinson's disease: cohort study of 32 patients
de Bie et al.
J. Neurol. Neurosurg. Psychiatry 2001;71:375-382.
ABSTRACT
| FULL TEXT
Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease
Lai et al.
Neurology 2000;55:1218-1222.
ABSTRACT
| FULL TEXT
|